F-Prime Capital’s Post

DarioHealth , the pioneering digital therapeutics platform hailing from Israel, continues to make waves in the industry. Established in 2011, DarioHealth has been at the forefront of delivering evidence-based interventions for chronic conditions. In a strategic move that underscores its commitment to innovation and growth, DarioHealth has just unveiled its acquisition of Twill, another prominent Digital Health venture. The deal, valued at $10 million upfront, alongside an additional $10 million in stock, with potential worth reaching upwards of $20 million, signifies a significant step forward for both companies. DarioHealth's leadership has articulated that this acquisition marks a pivotal moment, consolidating the strengths of both platforms to offer one of the most comprehensive digital solutions for chronic diseases and mental health in the market. They anticipate that pro forma earnings for 2023 are set to nearly double, with projected margins soaring above 80% by 2025. This strategic alignment also presents an opportunity to streamline costs, potentially reducing expenditures by almost a third. Curious about what exactly DarioHealth has acquired? Allow us to introduce Twill with a brief profile, shedding light on the synergies and innovations that lie ahead. #digitalhealth #acquisition #consolidation

Procyrion, Inc. secures $57.7m in Series E funding for Aortix device. This investment will support the pivotal DRAIN-HF IDE trial of the Aortix pMCS device, designed to aid patients with acute decompensated heart failure (ADHF) who are not responding to standard medical therapy. Patients with cardiorenal syndrome (CRS) often struggle with standard intravenous diuretic therapy, leading to a harmful cycle where heart failure reduces kidney blood flow, impairing fluid removal and further burdening the heart. “Approximately 25% of the millions of patients admitted to the hospital with ADHF are unable to be successfully treated with standard of care therapies, yet there is a lack of effective treatment options available, leading to very poor outcomes." - President & CEO, Eric Fain. Read the full press release below: https://lnkd.in/eHfumacU #Medexec #Procyrion #CardiorenalSyndrome #MedTechNews #Funding

Having a rest day before heading back to the UK and reflecting on what was a productive Phacilitate Advanced Therapies Week. The distributed manufacturing concept is gathering momentum, multiple sessions discussing the need for this approach as we expand the delivery of ATMPs to more patients. Important to recognise this is not in hospital point of care, too many variables and lack of control between sites means a market approved drug product cannot be manufactured in a POC setting. Digital systems, central to our model at adthera for assuring control of decentralised manufacturing centres, featured in more sessions and more conversations than I recall from previous years, the digital revolution is coming! All this as I hear from colleagues @Inmunebio of their first patient treated in a solid tumour clinical trial. The potential of these therapies to reach hundreds of thousands of patients a year is only a moment away, we need to build manufacturing capacity to service this need now! Another take home from this week has come from meetings with the financiers present at the meeting. The interest to invest is growing again, we need financial resources directing to the next generation of immunotherapy startups looking to develop manufacturing processes to enable more patient access to these innovative treatments, adthera bio is here to fast track that process dev, give me a shout if you think we can help. Final thoughts turn to how we get these therapies to patients and recognising the award to Robert Jones and his team at Cryoport. Worthy winners of the Simon Ellison memorial award, many of us worked with Simon and remember his drive to make this sector a success, I’m sure he’d be the first to congratulate Rob! So until next year in San Diego, adios. #ATW24 #adthera #ATMP #digitalfirst

It’s the Friday dive into news and updates across #woundcare, #footandankle and #limbsalvage this week 📅 ************************************************** 📈 Financial 📈 Vericel® Corporation – Announced a 23% increase in Q4 revenue and total year up 20% to $197.5M. MACI drove the majority of revenue followed by Burn Care led by Epicel and NexoBrid. Convatec – Announced full-year results including growth across all four categories. Full-year reported revenue grew 3.4% to $2.1B. Advanced Wound Care grew 9.5% driven by antimicrobial and growth across the wound biologics segment. This was in part the result of the previous acquisition of 30technology and their #nitricoxide platform. Pending Earnings announcements: - Sanara MedTech – Mar 27 ************************************************** 📢 News 📢 Spectral AI announced the formation of a wholly-owned subsidiary dedicated to advancing intellectual property relevant to the broader AI ecosystem, focused on healthcare. Organogenesis announced a license agreement with VIVEX Biologics to include the distribution of a new dehydrated, dual-layer #amniotic product marketed under the Cygnus brand. Gentell introduced Fastcare 2.0. Gentell Fastcare is an EHR system spanning 4,000 facilities with this upgrade offering #ai, 2-click supply replenishment and improved reporting according to President and CEO David Navazio. Innovative Outcomes announced the completion of their merger via SPAC with UbiquiTech Software Corp. Additionally, they announced they are set to launch “mywoundcare.com” incorporating #AI, #Imaging, custom kits and direct-to-patient shipments. ************************************************** 🔦 Spotlight on Innovation 🔦 Meeting new people, technologies and companies is truly enjoyable, and I love sharing what I learn. Do you have a new product or company, or know someone we should all get to know? Reach out - let me know! REV PHARMA CORPORATION USA – They have developed several innovative wound and skin therapies, currently leading with Carefini, an #otc offering demonstrating some impressive performance. Beyond OTC they are also developing a robust pipeline. I appreciated the outreach and enjoyed my conversation with Rodolfo Menazzi and Rallys Pliauzer. ************************************************** And that's it for this week, until next time. #woundcare #chronicwounds #limbsalvage #footandankle

Moneycontrol Exclusive: Here's the latest on a mega deal brewing in the healthcare space : A clutch of top global private equity funds, including EQT (formerly BPEA EQT), KKR, Bain Capital, and Advent International, are likely to have submitted initial bids as Apax Partners-promoted Healthium Medtech goes on the block in a mega deal that's likely to value the top medical devices firm at $750-850 million. More details below 👇 https://lnkd.in/dgnyd3tu

  Cresco is proud to announce that it has acted as lead counsel for the investment by Novalis Biotech, an early stage venture capital investor in life sciences, in the start-up RheumaFinder, founded by Nicolaas Fosselle (Chief Executive Officer), Dr. Thomas Van Den Berghe (Chief Medical Officer) and Professor Dr. Lennart Jans (Chief Science Officer).   RheumaFinder is a promising start-up developing an AI-powered application that detects signs of rheumatic diseases on a range of radiological imaging modalities. The application analyzes standard medical images requested for any clinical event to detect early signs of structural damage in joints. This early detection tool serves as an invaluable aid to radiologists and rheumatologists, contributing to sustainable healthcare practices by addressing the unmet clinical need of late- and underdiagnosis for rheumatic diseases.   The deal team consisted of Glenn L'hoëst and Dominik Verbist.   More information on this transaction and Rheumafinder’s technology and activities can be found in this article 👉 https://lnkd.in/eGDMA9RH on the website of Rheumafinder (https://lnkd.in/eubwQ7De)   For any further information or questions, please contact Glenn L'hoëst. #cresco #venturecapital #startup #healthcare  

Our latest Medsider playbook includes 5 lessons on how to efficiently navigate the regulatory landscape when developing novel #medicaldevices.   Key learnings from this playbook include: 🗺️ Map out your course by first building a focused prototype without excess complexity. 🤝 Ensure efficiency by engaging regulatory professionals from the start. ⚖️ Find balance by pairing regulatory boundary-pushers with conservative experts. 🗣️ Stay engaged through frequent and transparent dialogue with regulatory bodies. 🎓 Help regulators understand the nuances of your technology to fast-track approval. Read the full playbook (link in comments) to discover helpful lessons from the following #medtech founders and CEOs: ➡ Derek Herrera, CEO of Bright Uro ➡ Allison London Brown, CEO of LUMINELLE 360 ➡ Joe Landolina, CEO of Cresilon  ➡ Caroline J Loew, PhD, former CEO of Glympse Bio and current CEO of Mural Oncology  ➡ Sina Habibi, CEO of Cognetivity Neurosciences Ltd

Amber Therapeutics raises $100m - one of the largest series A's for a European Medtech 🇬🇧 💪 The UK-based medtech company has just closed their Series A financing round, raising $100 million (£80 million) from investors across the US and UK. This funding was led by New Enterprise Associates (NEA), and included F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises, and 8VC. Amber is pioneering an adaptive #neuromodulation therapy, Amber-UI, to treat mixed urinary incontinence (MUI) - a condition affecting millions of women worldwide. Amber-UI is the first fully implantable therapy targeting the pudendal nerve, designed to address both urge and stress incontinence through a minimally invasive procedure. Aidan Crawley, CEO of Amber said: "Securing this significant financing round from such a blue-chip group of US and UK investors is a huge validation of our therapy value proposition and the quality of the team we have built". Amber-UI, powered by the Picostim System, offers a unique approach by dynamically adapting to physiological responses, aiming to restore normal bladder function. Early results from their initial study "Aura 2" look promising, showing safety and strong efficacy signals. #funding #neurotech

⏳ Limited Time Offer: Bonus Shares Now Available! 💰 Invest before February 16th to maximize your stake in the cure to osteoarthritis. 🖇 invest.cytonics.com 🪙 Thinking About Investing? Grab Additional Bonus Shares Now! Don't miss this golden chance to boost your investment with bonus shares! From February 12th through the 16th, we're excited to offer a 10% additional bonus shares. This is your moment to make the most of your investment! 💰 Claim Your Bonus Shares Today: invest.cytonics.com 💎 Why Invest in Cytonics? 💵 Over $25M Raised: Strong financial backing, including J&J as a 14% shareholder. 📈 Progressing as Planned: FDA submission targeted and Phase 1 clinical trial launch 2Q24. 📝 Extensive IP Portfolio: 24 issued patents, with 4 additional pending. 👥 Expert Management: Over 100 years of collective experience in biotech R&D. 🌟 Commercial Success: Our FDA-approved APIC therapy and FACT diagnostic in market since 2015, generating $6M in total deal value with $500K annual royalties. 💲 Focused R&D Expenditure: 69% of investor funds allocated to R&D, achieving a debt-free status. 🌎 Invest In Quality Of Life Join Cytonics on our mission to conquer osteoarthritis and significantly improve the quality of life of millions worldwide. As a shareholder, you will directly contribute to a revolution in 💊 regenerative medicine, ensuring a much brighter future for you, your family, and all your loved ones as we age gracefully and demand a vibrant, pain free life into our Golden Years❤️ #biotechnology #drugdevelopment #clinicaltrials #crowdfunding #investing #arthritis